Published in Gut on February 21, 2006
Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis. Br J Pharmacol (2009) 1.07
Stellate cell contraction: role, regulation, and potential therapeutic target. Clin Liver Dis (2008) 0.91
Spironolactone lowers portal hypertension by inhibiting liver fibrosis, ROCK-2 activity and activating NO/PKG pathway in the bile-duct-ligated rat. PLoS One (2012) 0.86
Increased liver uptake and reduced hepatic stellate cell activation with a cell-specific conjugate of the Rho-kinase inhibitor Y27632. Pharm Res (2011) 0.84
Sodium Ferulate Reduces Portal Pressure Through Inhibition of RhoA/Rho-Kinase and Activation of Endothelial Nitric Oxide Synthase in Cirrhotic Rats. Dig Dis Sci (2015) 0.78
Reactive oxygen species are involved in regulating hypocontractility of mesenteric artery to norepinephrine in cirrhotic rats with portal hypertension. Int J Biol Sci (2014) 0.77
Interplay of Matrix Stiffness and c-SRC in Hepatic Fibrosis. Front Physiol (2015) 0.77
The CD47-binding peptide of thrombospondin-1 induces defenestration of liver sinusoidal endothelial cells. Liver Int (2013) 0.77
Rho-kinase/myosin light chain kinase pathway plays a key role in the impairment of bile canaliculi dynamics induced by cholestatic drugs. Sci Rep (2016) 0.76
Role of estrogen receptor β selective agonist in ameliorating portal hypertension in rats with CCl4-induced liver cirrhosis. World J Gastroenterol (2016) 0.75
Sodium ferulate lowers portal pressure in rats with secondary biliary cirrhosis through the RhoA/Rho-kinase signaling pathway: a preliminary study. Int J Mol Med (2014) 0.75
Future therapy of portal hypertension in liver cirrhosis - a guess. F1000Prime Rep (2014) 0.75
Novel treatment options for portal hypertension. Gastroenterol Rep (Oxf) (2017) 0.75
Rho GTPases in cell biology. Nature (2002) 22.81
Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature (1997) 14.91
Ca2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase. Physiol Rev (2003) 9.32
Rho GTPases and their effector proteins. Biochem J (2000) 8.89
Rocks: multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol (2003) 8.68
Signal transduction by G-proteins, rho-kinase and protein phosphatase to smooth muscle and non-muscle myosin II. J Physiol (2000) 5.24
Rho-kinase phosphorylates COOH-terminal threonines of ezrin/radixin/moesin (ERM) proteins and regulates their head-to-tail association. J Cell Biol (1998) 5.15
Phosphorylation of moesin by rho-associated kinase (Rho-kinase) plays a crucial role in the formation of microvilli-like structures. J Biol Chem (1998) 2.09
Association of the myosin-binding subunit of myosin phosphatase and moesin: dual regulation of moesin phosphorylation by Rho-associated kinase and myosin phosphatase. J Cell Biol (1998) 1.85
Hepatic stellate cells: role in microcirculation and pathophysiology of portal hypertension. Gut (2002) 1.82
Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: endothelial dysfunction in portal hypertension. Gastroenterology (1998) 1.68
Endothelin 1 is overexpressed in human cirrhotic liver and exerts multiple effects on activated hepatic stellate cells. Gastroenterology (1996) 1.66
RhoA-dependent phosphorylation and relocalization of ERM proteins into apical membrane/actin protrusions in fibroblasts. Mol Biol Cell (1998) 1.62
Hepatic blood flow regulation by stellate cells in normal and injured liver. Semin Liver Dis (2001) 1.62
Impaired endothelial nitric oxide synthase activity associated with enhanced caveolin binding in experimental cirrhosis in the rat. Gastroenterology (1999) 1.58
The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. Hepatology (2002) 1.57
Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats. Hepatology (1998) 1.47
The cellular pathogenesis of portal hypertension: stellate cell contractility, endothelin, and nitric oxide. Hepatology (1997) 1.34
Rho activation in excitatory agonist-stimulated vascular smooth muscle. Am J Physiol Cell Physiol (2001) 1.33
Pharmacomechanical coupling: the role of calcium, G-proteins, kinases and phosphatases. Rev Physiol Biochem Pharmacol (1999) 1.26
Mechanisms of nitric oxide interplay with Rho GTPase family members in modulation of actin membrane dynamics in pericytes and fibroblasts. Am J Pathol (2005) 1.22
Liver sinusoidal endothelial cells are responsible for nitric oxide modulation of resistance in the hepatic sinusoids. J Clin Invest (1997) 1.20
Portal hypertension: from bedside to bench. J Clin Gastroenterol (2005) 1.16
A p160ROCK-specific inhibitor, Y-27632, attenuates rat hepatic stellate cell growth. J Hepatol (2000) 1.09
Lysophosphatidic acid enhances collagen gel contraction by hepatic stellate cells: association with rho-kinase. Biochem Biophys Res Commun (2000) 1.09
Inhibitory effect of Y-27632, a ROCK inhibitor, on progression of rat liver fibrosis in association with inactivation of hepatic stellate cells. J Hepatol (2001) 1.08
Enhanced expression of CD80 (B7-1), CD86 (B7-2), and CD40 and their ligands CD28 and CD154 in fulminant hepatic failure. Am J Pathol (1999) 1.06
Gene transfer of the neuronal NO synthase isoform to cirrhotic rat liver ameliorates portal hypertension. J Clin Invest (2000) 1.06
A selective ROCK inhibitor, Y27632, prevents dimethylnitrosamine-induced hepatic fibrosis in rats. J Hepatol (2001) 1.01
ROCK inhibitor Y-27632 attenuates stellate cell contraction and portal pressure increase induced by endothelin-1. Biochem Biophys Res Commun (1999) 0.99
Increased hepatic resistance: a new target in the pharmacologic therapy of portal hypertension. J Clin Gastroenterol (2005) 0.99
Measurement of organ blood flow with coloured microspheres in the rat. Cardiovasc Res (1995) 0.98
Actin filament formation, reorganization and migration are impaired in hepatic stellate cells under influence of trichostatin A, a histone deacetylase inhibitor. J Hepatol (2002) 0.98
Lysophosphatidic acid-induced platelet shape change proceeds via Rho/Rho kinase-mediated myosin light-chain and moesin phosphorylation. Cell Signal (2000) 0.98
Increased hepatic endothelin-1 levels and endothelin receptor density in cirrhotic rats. Life Sci (1996) 0.95
Cellular and molecular basis of portal hypertension. Clin Liver Dis (2001) 0.93
Portal venous pressure and portasystemic shunting in experimental portal hypertension. Am J Physiol (1989) 0.93
Role of Rho small GTP binding protein in the regulation of actin cytoskeleton in hepatic stellate cells. J Hepatol (1999) 0.92
Therapeutic significance of Y-27632, a Rho-kinase inhibitor, on the established liver fibrosis. J Surg Res (2003) 0.90
Activation of moesin and adducin by Rho-kinase downstream of Rho. Biophys Chem (1999) 0.89
Cyclooxygenase-derived products modulate the increased intrahepatic resistance of cirrhotic rat livers. Hepatology (2003) 0.88
Deficit in nitric oxide production in cirrhotic rat livers is located in the sinusoidal and postsinusoidal areas. Am J Physiol Gastrointest Liver Physiol (2002) 0.88
Angiotensin II participates in hepatic inflammation and fibrosis through MCP-1 expression. Dig Dis Sci (2005) 0.87
Characterisation of portal hypertension models by microspheres in anaesthetised rats: a comparison of liver flow. Pharmacol Ther (2001) 0.87
Anesthetic influences on regional hemodynamics in normal and hemorrhaged rats. Anesthesiology (1984) 0.86
Mixed endothelin receptor antagonist, SB209670, decreases portal pressure in biliary cirrhotic rats in vivo by reducing portal venous system resistance. J Hepatol (2000) 0.85
Bioactivation of nitroglycerin and vasomotor response to nitric oxide are impaired in cirrhotic rat livers. Hepatology (2002) 0.84
Regional and systemic hemodynamic disturbances in cirrhosis. Clin Liver Dis (2001) 0.83
5-lipoxygenase inhibition reduces intrahepatic vascular resistance of cirrhotic rat livers: a possible role of cysteinyl-leukotrienes. Gastroenterology (2002) 0.82
Acute haemodynamic effects of losartan in anaesthetized cirrhotic rats. Eur J Clin Invest (2003) 0.82
Enhanced vasoconstrictor response of the isolated perfused cirrhotic rat liver to humoral vasoconstrictor substances found in portal venous blood. J Gastroenterol Hepatol (1992) 0.81
Prevention of ischemia-reperfusion-induced hepatic microcirculatory disruption by inhibiting stellate cell contraction using rock inhibitor. Transplantation (2003) 0.78
Endothelin-induced vasoconstriction in isolated perfused liver preparations from normal and cirrhotic rats. J Gastroenterol Hepatol (1997) 0.77
Shock-wave lithotripsy of gallbladder stones. The first 175 patients. N Engl J Med (1988) 5.53
Regulation of DAF-2 receptor signaling by human insulin and ins-1, a member of the unusually large and diverse C. elegans insulin gene family. Genes Dev (2001) 3.59
Fragmentation of gallstones by extracorporeal shock waves. N Engl J Med (1986) 2.76
Transjugular intrahepatic portosystemic shunting is not superior to endoscopic variceal band ligation for prevention of variceal rebleeding in cirrhotic patients: a randomized, controlled trial. Scand J Gastroenterol (2002) 2.54
A citric acid solution is an optimal test drink in the 13C-urea breath test for the diagnosis of Helicobacter pylori infection. Gut (1997) 2.32
Topographic association between active gastritis and Campylobacter pylori colonisation. J Clin Pathol (1989) 2.09
Visual evoked potentials in adrenoleukodystrophy: a trial with glycerol trioleate and Lorenzo oil. Ann Neurol (1993) 2.07
[S3-Guidelines Conference "Colorectal Carcinoma" 2004]. Z Gastroenterol (2004) 2.03
Clostridium difficile infection in patients with neutropenia. Clin Infect Dis (2001) 2.00
Surface expression and cytolytic function of natural killer cell receptors is altered in chronic hepatitis C. Gut (2005) 1.99
Evaluation of an ultrasound-guided technique for central venous access via the internal jugular vein in 493 patients. Support Care Cancer (2002) 1.95
T- and B-cell responses to different hepatitis C virus antigens in patients with chronic hepatitis C infection and in healthy anti-hepatitis C virus--positive blood donors without viremia. Hepatology (1996) 1.88
Difference in expression of Helicobacter pylori gastritis in antrum and body. Gastroenterology (1992) 1.70
Dormia baskets impacted in the bile duct: release by extracorporeal shock-wave lithotripsy. Endoscopy (1995) 1.70
Increased frequency of the HLA-DR15 (B1*15011) allele in German patients with self-limited hepatitis C virus infection. Eur J Clin Invest (1999) 1.68
Structure of visual pigments. I. Purification, molecular weight, and composition of bovine visual pigment500. Biochemistry (1968) 1.64
Comparison of capsule endoscopy and magnetic resonance imaging for the detection of polyps of the small intestine in patients with familial adenomatous polyposis or with Peutz-Jeghers' syndrome. Endoscopy (2004) 1.64
Gallstones: pathogenesis. Lancet (1991) 1.64
Toll-like receptor (TLR) 2 promoter and intron 2 polymorphisms are associated with increased risk for spontaneous bacterial peritonitis in liver cirrhosis. J Hepatol (2011) 1.62
Gallstone recurrence after shock-wave therapy. Gastroenterology (1994) 1.59
Renal excretory mechanisms of heavy metals. I. Transtubular transport of heavy metal ions in the avian kidney. Environ Res (1968) 1.57
Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine. Br J Cancer (2003) 1.57
Long-term results and prognostic factors in the treatment of achalasia with botulinum toxin. Endoscopy (2002) 1.51
Low-molecular weight proteins as markers for glomerular filtration rate. Clin Chem (2001) 1.50
Tumor necrosis factor alpha in the pathogenesis of human and murine fulminant hepatic failure. Gastroenterology (2000) 1.49
Prediction of variceal hemorrhage in cirrhosis: a prospective follow-up study. Gastroenterology (1991) 1.47
Clinical characteristics and outcome of a cohort of 101 patients with hepatocellular carcinoma. World J Gastroenterol (2001) 1.47
Six bioabsorbable polymers: in vitro acute toxicity of accumulated degradation products. J Appl Biomater (1994) 1.47
Comparison of portal vein velocity and the hepatic venous pressure gradient in assessing the acute portal hemodynamic response to propranolol in patients with cirrhosis. Am J Gastroenterol (2000) 1.46
[Symptoms, tumor stage and primary treatment in patients with colorectal carcinoma]. Dtsch Med Wochenschr (1997) 1.46
Interactions of plasma retinol-binding protein with its receptor. Specific binding of bovine and human retinol-binding protein to pigment epithelium cells from bovine eyes. J Biol Chem (1975) 1.42
Surgical intervention following fragmentation of gallstones by extracorporeal shock waves. World J Surg (1989) 1.42
[Fecal incontinence]. Internist (Berl) (2000) 1.42
Serum bile acids: physiology and clinical relevance. Eur J Gastroenterol Hepatol (1995) 1.41
[Therapy-refractory thrombocytopenia in chronic hepatitis C]. Z Gastroenterol (2000) 1.39
[The therapy of the hepatorenal syndrome in liver cirrhosis]. Dtsch Med Wochenschr (1999) 1.39
Autoimmunity induced by interferon-alpha therapy for chronic viral hepatitis. Biomed Pharmacother (1999) 1.33
Mixed-strain infection with a drug-sensitive and multidrug-resistant strain of Mycobacterium tuberculosis. Lancet (1995) 1.32
A novel minimal-size vector (MIDGE) improves transgene expression in colon carcinoma cells and avoids transfection of undesired DNA. Mol Ther (2001) 1.28
Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines. Cell Immunol (2000) 1.28
Definitions, methodology and therapeutic strategies in portal hypertension. A Consensus Development Workshop, Baveno, Lake Maggiore, Italy, April 5 and 6, 1990. J Hepatol (1992) 1.27
Fecal elastase test: evaluation of a new noninvasive pancreatic function test. Am J Gastroenterol (1995) 1.27
Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertension. Gastroenterology (2001) 1.25
Role of nitric oxide in hepatopulmonary syndrome in cirrhotic rats. Am J Respir Crit Care Med (2001) 1.23
The Munich Gallbladder Lithotripsy Study. Results of the first 5 years with 711 patients. Ann Intern Med (1991) 1.23
Mechanisms of extrahepatic vasodilation in portal hypertension. Gut (2008) 1.23
Subjective well-being and 'male depression' in male adolescents. J Affect Disord (2006) 1.21
Interactions between dendritic cells and cytokine-induced killer cells lead to an activation of both populations. J Immunother (2001) 1.21
S3 guidelines for colorectal carcinoma: results of an evidence-based consensus conference on February 6/7, 2004 and June 8/9, 2007 (for the topics IV, VI and VII). Z Gastroenterol (2010) 1.20
Decreased frequency of HCV core-specific peripheral blood mononuclear cells with type 1 cytokine secretion in chronic hepatitis C. J Hepatol (1999) 1.20
Calculation of glomerular filtration rate based on cystatin C in cirrhotic patients. Nephrol Dial Transplant (2005) 1.20
A retrospective analysis of 3 year's experience of an interdisciplinary approach to gallstone disease including shock-waves. Ann Surg (1988) 1.19
Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology (1992) 1.19
Shock-wave therapy of gastric outlet syndrome caused by a gallstone. Gastroenterology (1989) 1.19
Transport of retinol from the blood to the retina: an autoradiographic study of the pigment epithelial cell surface receptor for plasma retinol-binding protein. Exp Eye Res (1976) 1.18
Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. J Viral Hepat (2006) 1.17
Comparative study of a membrane protein. Characterization of bovine, rat, and frog visual pigments500. Biochemistry (1969) 1.17
Modified rapid urease test for detection of Helicobacter pylori infection. Eur J Gastroenterol Hepatol (1996) 1.16
Chromocolonoscopy detects more adenomas than white light colonoscopy or narrow band imaging colonoscopy in hereditary nonpolyposis colorectal cancer screening. Endoscopy (2009) 1.16
Studies on the regulation of ornithine decarboxylase activity by the microtubules: the effect of colchicine and vinblastine. Biochem Biophys Res Commun (1976) 1.15
Proposal of a 2-tier histologic grading system for canine cutaneous mast cell tumors to more accurately predict biological behavior. Vet Pathol (2010) 1.14
Intestinal involvement in progressive systemic sclerosis detected by increased unconjugated serum bile acids. Gut (1987) 1.14
The enhancement of fluorescence and the decreased susceptibility to enzymatic oxidation of retinol complexed with bovine serum albumin, -lactoglobulin, and the retinol-binding protein of human plasma. J Biol Chem (1972) 1.13
Correlation of serum concentrations of cystatin C and creatinine to inulin clearance in liver cirrhosis. Clin Chem (2000) 1.13
The osmotic behavior of rod photoreceptor outer segment discs. J Cell Biol (1971) 1.12
Uptake of retinol and retinoic acid from serum retinol-binding protein by retinal pigment epithelial cells. J Biol Chem (1977) 1.11
Evidence for down-regulation of beta-2-adrenoceptors in cirrhotic patients with severe ascites. Lancet (1986) 1.11
Littoral cell angioma as a rare cause of splenomegaly. Ann Hematol (2001) 1.11
Endoscopy in the diagnosis of gastritis. Diagnostic value of endoscopic criteria in relation to histological diagnosis. Endoscopy (1984) 1.10
Immunosuppression may lead to progression of hepatitis C virus-associated liver disease in hemophiliacs coinfected with HIV. Am J Gastroenterol (1996) 1.10
Performance evaluation of the Abbott HTLV III EIA, a test for antibody to HTLV III in donor blood. Am J Clin Pathol (1986) 1.08
Force-velocity relationship and maximal power on a cycle ergometer. Correlation with the height of a vertical jump. Eur J Appl Physiol Occup Physiol (1987) 1.08
CD30 induction and cytokine profiles in hepatitis C virus core-specific peripheral blood T lymphocytes. J Immunol (1997) 1.08
Three-dimensional magnetic resonance cholangiopancreatography with respiratory triggering in the diagnosis of primary sclerosing cholangitis: comparison with endoscopic retrograde cholangiography. Endoscopy (2002) 1.07
Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis. Br J Pharmacol (2009) 1.07
Influence of cytokines, monoclonal antibodies and chemotherapeutic drugs on epithelial cell adhesion molecule (EpCAM) and LewisY antigen expression. Clin Exp Immunol (2001) 1.07
The renal endothelin system in the Prague hypertensive rat, a new model of spontaneous hypertension. Clin Sci (Lond) (1999) 1.06
Microsatellite instability did not predict individual survival of unselected patients with colorectal cancer. Int J Colorectal Dis (2006) 1.06
Enhanced expression of CD80 (B7-1), CD86 (B7-2), and CD40 and their ligands CD28 and CD154 in fulminant hepatic failure. Am J Pathol (1999) 1.06
Early gallstone recurrence rate after successful shock-wave therapy. Gastroenterology (1990) 1.06
"Atypical p-ANCA" in IBD and hepatobiliary disorders react with a 50-kilodalton nuclear envelope protein of neutrophils and myeloid cell lines. Gastroenterology (2000) 1.06
Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole. Mycoses (1999) 1.06
Esophageal function after sclerotherapy of bleeding varices. Scand J Gastroenterol (1982) 1.05
The Quebec hemovigilance system: description and results from the first two years. Transfus Apher Sci (2004) 1.05
Relative utilization of reptiles and rodents as hosts by immature Ixodes scapularis (Acari: Ixodidae) in the coastal plain of North Carolina, USA. Exp Appl Acarol (1993) 1.03
Enhanced lytic activity of cytokine-induced killer cells against multiple myeloma cells after co-culture with idiotype-pulsed dendritic cells. Haematologica (2001) 1.02
All out anaerobic capacity tests on cycle ergometers. A comparative study on men and women. Eur J Appl Physiol Occup Physiol (1985) 1.02
Sodium selenite and N-acetylcysteine in antiretroviral-naive HIV-1-infected patients: a randomized, controlled pilot study. Eur J Clin Invest (1998) 1.02
Simultaneous determination of cholic acid and chenodeoxycholic acid pool sizes and fractional turnover rates in human serum using 13C-labeled bile acids. J Lipid Res (1984) 1.01
Very early detection of response to imatinib mesylate therapy of gastrointestinal stromal tumours using 18fluoro-deoxyglucose-positron emission tomography. Anticancer Res (2005) 1.01